Thomas G. Todaro

1.8k total citations
29 papers, 1.3k citations indexed

About

Thomas G. Todaro is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Biomedical Engineering. According to data from OpenAlex, Thomas G. Todaro has authored 29 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Cardiology and Cardiovascular Medicine, 11 papers in Surgery and 9 papers in Biomedical Engineering. Recurrent topics in Thomas G. Todaro's work include Acute Myocardial Infarction Research (13 papers), Cardiac electrophysiology and arrhythmias (10 papers) and Mechanical Circulatory Support Devices (9 papers). Thomas G. Todaro is often cited by papers focused on Acute Myocardial Infarction Research (13 papers), Cardiac electrophysiology and arrhythmias (10 papers) and Mechanical Circulatory Support Devices (9 papers). Thomas G. Todaro collaborates with scholars based in United States, Canada and United Kingdom. Thomas G. Todaro's co-authors include Paul W. Armstrong, Christopher B. Granger, Kenneth W. Mahaffey, Thomas G. Filloon, Pierre Théroux, Judith S. Hochman, W. Douglas Weaver, José Carlos Nicolau, Peter X. Adams and Scott A. Rollins and has published in prestigious journals such as JAMA, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Thomas G. Todaro

29 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas G. Todaro United States	16	721	390	330	245	202	29	1.3k
Albert W. Chan Canada	21	1.3k 1.7×	876 2.2×	410 1.2×	416 1.7×	33 0.2×	76	2.2k
D Mathey Germany	12	882 1.2×	545 1.4×	185 0.6×	390 1.6×	120 0.6×	39	1.5k
Jane C.K. Fitch United States	15	339 0.5×	526 1.3×	227 0.7×	76 0.3×	117 0.6×	30	1.2k
Stephanie L. Mick United States	18	816 1.1×	583 1.5×	196 0.6×	64 0.3×	124 0.6×	57	1.4k
Ignacio Duarte Chile	23	315 0.4×	962 2.5×	221 0.7×	44 0.2×	169 0.8×	70	1.8k
Charlotte S. Roberts United States	11	844 1.2×	278 0.7×	247 0.7×	360 1.5×	74 0.4×	21	1.4k
Megan H. MacNabb United States	11	285 0.4×	180 0.5×	271 0.8×	177 0.7×	55 0.3×	17	900
Lorenz Koller Austria	21	491 0.7×	158 0.4×	225 0.7×	69 0.3×	34 0.2×	70	1.0k
Françis Juthier France	20	1.1k 1.6×	723 1.9×	80 0.2×	156 0.6×	24 0.1×	81	1.9k
Yasmin S. Hamirani United States	17	712 1.0×	303 0.8×	45 0.1×	490 2.0×	48 0.2×	74	1.1k

Countries citing papers authored by Thomas G. Todaro

Since Specialization

Citations

This map shows the geographic impact of Thomas G. Todaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas G. Todaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas G. Todaro more than expected).

Fields of papers citing papers by Thomas G. Todaro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas G. Todaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas G. Todaro. The network helps show where Thomas G. Todaro may publish in the future.

Co-authorship network of co-authors of Thomas G. Todaro

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas G. Todaro. A scholar is included among the top collaborators of Thomas G. Todaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas G. Todaro. Thomas G. Todaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Idriss, Salim F., Stuart Berger, Kimberly G. Harmon, et al.. (2017). Prevention of sudden cardiac death in the young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium. American Heart Journal. 190. 123–131. 6 indexed citations

Heller, Simon, Börje Darpö, Malcolm I. Mitchell, et al.. (2015). Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium. American Heart Journal. 170(1). 23–35. 7 indexed citations

Finkle, John K., Norman Stockbridge, Kaori Shinagawa, et al.. (2015). Cardiac Safety Research Consortium (CSRC): Cardiovascular Safety and Adverse Event Case Report Forms. Therapeutic Innovation & Regulatory Science. 49(4). 511–513. 1 indexed citations

Geiger, Mary Jane, Cyrus R. Mehta, J. Rick Turner, et al.. (2014). Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes. Therapeutic Innovation & Regulatory Science. 49(1). 50–64. 14 indexed citations

Mahaffey, Kenneth W., Yuliya Lokhnygina, José Carlos Nicolau, et al.. (2012). Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction. Coronary Artery Disease. 23(2). 118–125. 4 indexed citations

Smith, Peter K., Stanton K. Shernan, John C. Chen, et al.. (2010). Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: Combined results from the PRIMO-CABG I and II trials. Journal of Thoracic and Cardiovascular Surgery. 142(1). 89–98. 56 indexed citations

Tjandrawidjaja, Michael C., Ya–Yuan Fu, Cynthia M. Westerhout, et al.. (2009). Resolution of ST-segment depression: a new prognostic marker in ST-segment elevation myocardial infarction. European Heart Journal. 31(5). 573–581. 23 indexed citations

Brener, Sorin J., Cynthia M. Westerhout, Yuling Fu, et al.. (2009). Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. American Heart Journal. 158(5). 755–760. 7 indexed citations

Armstrong, Paul W., Yuling Fu, Cynthia M. Westerhout, et al.. (2009). Baseline Q-Wave Surpasses Time From Symptom Onset as a Prognostic Marker in ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 53(17). 1503–1509. 53 indexed citations

10.

Mahaffey, Kenneth W., Craig J. Reist, Yuling Fu, et al.. (2008). Integrating ancillary studies in a large clinical trial: The design and rationale of the APEX library. Contemporary Clinical Trials. 29(6). 887–895. 8 indexed citations

11.

Armstrong, Paul W., Kenneth W. Mahaffey, Wei-Ching Chang, et al.. (2006). Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. American Heart Journal. 151(4). 787–790. 15 indexed citations

12.

Smith, Peter K., Michel Carrier, John C. Chen, et al.. (2006). Effect of Pexelizumab in Coronary Artery Bypass Graft Surgery With Extended Aortic Cross-Clamp Time. The Annals of Thoracic Surgery. 82(3). 781–789. 28 indexed citations

13.

Armstrong, Paul W., Peter X. Adams, Christian W. Hamm, et al.. (2006). Assessment of pexelizumab in acute myocardial infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 114(22). 2425–2425. 3 indexed citations

14.

Carrier, M., Philippe Menasché, Jerrold H. Levy, et al.. (2006). Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery. 131(2). 352–356. 28 indexed citations

15.

Haverich, Axel, Stanton K. Shernan, Jerrold H. Levy, et al.. (2006). Pexelizumab Reduces Death and Myocardial Infarction in Higher Risk Cardiac Surgical Patients. The Annals of Thoracic Surgery. 82(2). 486–492. 20 indexed citations

16.

Mahaffey, Kenneth W., Frans Van de Werf, Stanton K. Shernan, et al.. (2006). Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: A systematic overview. American Heart Journal. 152(2). 291–296. 30 indexed citations

17.

Goyal, Abhinav, Kenneth W. Mahaffey, Jyotsna Garg, et al.. (2006). Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. European Heart Journal. 27(11). 1289–1297. 135 indexed citations

18.

Armstrong, Paul W., Peter X. Adams, Hussein R. Al‐Khalidi, et al.. (2005). Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. American Heart Journal. 149(3). 402–407. 47 indexed citations

19.

Werf, Frans Van de, Paul W. Armstrong, Jerrold H. Levy, et al.. (2004). 810-4 Pexelizumab, a C5 complement inhibitor, reduces 30-day mortality in patients undergoing coronary artery bypass surgery or receiving reperfusion therapy for acute myocardial infarction. Journal of the American College of Cardiology. 43(5). A474–A474. 1 indexed citations

20.

Verrier, Edward D., Stanton K. Shernan, Kenneth M. Taylor, et al.. (2004). Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass. JAMA. 291(19). 2319–2319. 138 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact